1 / 11

Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON

This study evaluates the efficacy of Sofosbuvir combined with Ribavirin in patients with Hepatitis C virus (HCV) genotypes 2 and 3 who are intolerant to or unwilling to take interferon, as well as those ineligible for it. The POSITRON trial involved a 12-week treatment regimen with a significant sustained virologic response (SVR) rate observed at week 12 post-treatment. Key findings include the treatment's effectiveness across different genotypes and liver disease stages, indicating a promising option for patients with limited treatment choices.

Olivia
Télécharger la présentation

Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Interferon Intolerant, Unwilling, or Ineligible Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option)POSITRON *Note: Published in tandem with FUSION Trial (GT 2,3 and prior failure with PEG) Jacobson I, et al. N Engl J Med. 2013;368:1867-77.

  2. Sofosbuvir + Ribavirin for HCV GT 2 or 3 (PEG not an option)POSITRON Trial: Design Source: Jacobson I,et al. N Engl J Med. 2013;368:1867-77.

  3. Sofosbuvir + Ribavirin for HCV GT 2 or 3 (PEG not an option)POSITRON Trial: Design 0 12 24 Week Sofosbuvir+ RBV 12 weeks N =207 SVR12 Placebo12 weeks N =71 SVR12 Drug DosingSofosbuvir: 400 mg once dailyWeight-Based Ribavirin (in 2 divided doses): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Jacobson I, et al. N Engl J Med. 2013;368:1867-77.

  4. Sofosbuvir + Ribavirin for HCV GT 2 or 3 (PEG not an option)POSITRON Trial: Reasons for Interferon Ineligibility Source: Jacobson I, et al. N Engl J Med. 2013;368:1867-77.

  5. Sofosbuvir + Ribavirin for HCV GT 2 or 3 (PEG not an option)POSITRON Trial: Duration on Prior Interferon Source: Jacobson I, et al. N Engl J Med. 2013;368:1867-77.

  6. Sofosbuvir for HCV Infection GT 2,3 (PEG not an option)POSITRON: Results with Sofosbuvir + Ribavirin POSITRON: Patients with HCV RNA <25 IU/ml by Study Timepoint 202/204 202/202 161/207 Placebo arm: 0% for each timepointAbbreviations: SOF = sofosbuvir; RBV = ribavirin Source: Jacobson I, et al. N Engl J Med. 2013;368:1867-77.

  7. Sofosbuvir + Ribavirin for HCV GT 2,3 (PEG not an option)POSITRON: Results with Sofosbuvir + Ribavirin POSITRON: SVR12 by HCV Genotype 101/109 60/98 Placebo arm: 0% for each timepoint Source: Jacobson I, et al. N Engl J Med. 2013;368:1867-77.

  8. Sofosbuvir + Ribavirin for HCV GT 2,3 (PEG not an option)POSITRON: Results with Sofosbuvir + Ribavirin POSITRON: SVR12 by Liver Disease 142/176 19/31 Placebo arm: 0% for each timepoint Source: Jacobson I, et al. N Engl J Med. 2013;368:1867-77.

  9. Sofosbuvir + Ribavirin for HCV GT 2,3 (PEG not an option)POSITRON: Results with Sofosbuvir + Ribavirin POSITRON: SVR12 by Liver Disease and Genotype 85/92 16/17 57/84 3/14 Placebo arm: 0% for each timepoint Source: Jacobson I, et al. N Engl J Med. 2013;368:1867-77.

  10. Sofosbuvir + Ribavirin for HCV GT 2,3 (PEG not an option)POSITRON Trial: Conclusions *Note: This conclusion pertains to both the POSITRON and FUSION trials, which were published in tandem Source: Jacobson I, et al. N Engl J Med. 2013;368:1867-77.

  11. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related